Clinical applications of vascular gene therapy

Current Cardiology Reports

Volumn 3, Issue 1, 2001, Pages 29-36

  Rutanen, Juha ^a   Rissanen, Tuomas T ^a   Kivelä, Antti ^a   Vajanto, Ismo ^a   Ylä Herttuala, Seppo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; LYMPHOKINE; VASCULOTROPIN; VASCULOTROPIN A;

ADENOVIRUS; ANIMAL; CORONARY ARTERY DISEASE; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; GRAFT OCCLUSION; HUMAN; RECURRENT DISEASE; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADENOVIRIDAE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CORONARY DISEASE; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTORS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRAFT OCCLUSION, VASCULAR; HUMANS; LYMPHOKINES; RECURRENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035229101     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0007-z     Document Type: Article

References (56)

1. Ylä-Herttuala S, Martin JF: Cardiovascular gene therapy. Lancet 2000, 355:213-222.
2. Laitinen M, Mäkinen K, Manninen H, et al.: Adenovirusmediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther 1998, 9:1481-1486.
3. Baumgartner I, Pieczek A, Manor O, et al.: Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998, 97:1114-1123.
4. Rosengart TK, Lee LY, Patel SR, et al.: Angiogenesis gene therapy : phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999, 100:468-474.
5. Losordo DW, Vale PR, Symes JF, et al.: Gene therapy for myocardial angiogenesis - Initial clinical results with direct myocardial injection of phVEGF(165) as sole therapy for myocardial ischemia. Circulation 1998, 98:2800-2804.
6. Symes JF, Losordo DW, Vale PR, et al.: Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999, 68:830-836.
7. Laitinen M, Hartikainen J, Hiltunen MO, et al.: Cathetermediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 2000, 11:263-270.
8. Hiltunen MO, Turunen MP, Turunen AM, et al.: Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation 2000, 102: 2262-2268
9. Cavazzana-Calvo M, Hacein-Bey S, de Saint B, et al.: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288:669-672.
10. Khuri FR, Nemunaitis J, Ganly I, et al.: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000, 6:879-885.
11. Laitinen M, Pakkanen T, Donetti E, et al.: Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid- liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum Gene Ther 1997, 8:1645-1650.
12. Turunen MP, Hiltunen MO, Ruponen M, et al.: Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer-plasmid complexes. Gene Ther 1999, 6:6-11.
13. Laitinen M, Zachary I, Breier G, et al.: Vegf gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther 1997, 8:1737-1744.
14. Sirois MG, Simons M, Edelman ER: Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening. Circulation 1997, 95:669-676.
15. Mäkinen K, Laitinen M, Manninen H, et al.: Catheter-mediated VEGF gene transfer to human lower limb arteries after PTA [abstract]. Circulation 1999, 100:I-770.
16. Hiltunen MO, Turunen MP, Turunen AM, et al.: Biodistribution of adenoviral vector to non-target tissues after in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J 2000, 14: 2230-2236
17. Randall JL, Springer ML, Blanco-Bose WE, et al.: VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000, 102:898-903.
18. Nalbantoglu J, Pari G, Karpati G, Holland PC: Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum Gene Ther 1999, 10:1009-1019.
19. Binley K, Iqball S, Kingsman A, et al.: An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther 1999, 6:1721-1727.
20. Pakkanen TM, Laitinen M, Hippeläinen M, et al.: Enhanced plasma cholesterol lowering effect of retrovirus- mediated LDL receptor gene transfer to WHHL rabbit liver after improved surgical technique and stimulation of hepatocyte proliferation by combined partial liver resection and thymidine kinase ganciclovir treatment. Gene Ther 1999, 6:34-41.
21. Grossman M, Rader DJ, Muller DW, et al.: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995, 1:1148-1154.
22. Isner JM, Pieczek A, Schainfeld R, et al.: Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996, 348:370-374.
23. Isner JM, Baumgartner I, Rauh G, et al.: Treatment of thromboangitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998, 28:964-973.
24. Lee LY, Patel SR, Hackett NR, et al.: Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg 2000, 69:14-23.
25. Esakof DD, Maysky M, Losordo DW, et al.: Intraoperative multiplane transesophageal echocardiography for guiding direct myocardial gene transfer of vascular endothelial growth factor in patients with refractory angina pectoris. Hum Gene Ther 1999, 10:2307-2314.
26. Lamping KG, Rios CD, Chun JA, et al.: Intrapericardial administration of adenovirus for gene transfer. Am J Physiol 1997, 272:H310-H317.
27. Mann MJ, Whittemore AD, Donaldson MC, et al.: Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999, 354:1493-1498.
28. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
29. Tsurumi Y, Takeshita S, Chen D, et al.: Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996, 94:3281-3290.
30. Mack CA, Patel SR, Schwarz EA, et al.: Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998, 115:168-176.
31. Witzenbichler B, Asahara T, Murohara T, et al.: Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 1998, 153:381-394.
32. Lopez JJ, Edelman ER, Stamler A, et al.: Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. Am J Physiol 1998, 274:H930-H936.
33. Galzie Z, Kinsella AR, Smith JA: Fibroblast growth factors and their receptors. Biochem Cell Biol 1997, 75:669-685.
34. Thurston G, Rudge JS, Ioffe E, et al.: Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000, 6:460-463.
35. Kalka C, Masuda H, Takahashi T, et al.: Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000, 86:1198-1202.
36. Pecher P, Schumacher BA: Angiogenesis in ischemic human myocardium: clinical results after 3 years. Ann Thorac Surg 2000, 69:1414-1419.
37. Van Belle E, Rivard A, Chen D, et al.: Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 1997, 96:2667-2674.
38. Rivard A, Berthou-Soulie L, Principe N, et al.: Age-dependent defect in VEGF expression is associated with reduced HIF-1 activity. J Biol Chem 2000, 275: 29643-29647
39. Waltenberger J, Lange J, Kranz A: Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation 2000, 102:185-190.
40. Rade JJ, Schulick AH, Virmani R, Dichek DA: Local adenoviralmediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med 1996, 2:293-298.
41. Waugh JM, Kattash M, Li J, et al.: Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci U S A 1999, 96:1065-1070.
42. Schwartz RS: Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol 1998, 81:14E-17E.
43. Jawien A, Bowen-Pope DF, Lindner V, et al.: Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992, 89:507-511.
44. Deguchi J, Namba T, Hamada H, et al.: Targeting endogenous platelet-derived growth factor B-chain by adenovirusmediated gene transfer potently inhibits in vivo smooth muscle proliferation after arterial injury. Gene Ther 1999, 6:956-965.
45. Cheng L, Mantile G, Pauly R, et al.: Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation 1998, 98:2195-2201.
46. Asahara T, Bauters C, Pastore C, et al.: Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995, 91:2793-2801.
47. Virmani R, Farb A: Pathology of in-stent restenosis. Curr Opin Lipidol 1999, 10:499-506.
48. McKenna CJ, Camrud AR, Sangiorgi G, et al.: Fibrin-film stenting in a porcine coronary injury model: efficacy and safety compared with uncoated stents. J Am Coll Cardiol 1998, 31:1434-1438.
49. Laukkanen J, Lehtolainen P, Gough PJ, et al.: Adenovirusmediated gene transfer of a secreted form of human macrophage scavenger receptor inhibits modified lowdensity lipoprotein degradation and foam-cell formation in macrophages. Circulation 2000, 101:1091-1096.
50. Schumacher B, Pecher P, von Specht BU, Stegmann T: Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998, 97:645-650.
51. Laham RJ, Sellke FW, Edelman ER, et al.: Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999, 100:1865-1871.
52. Lindner V, Reidy MA: Expression of VEGF receptors in arteries after endothelial injury and lack of increased endothelial regrowth in response to VEGF. Arterioscler Thromb Vasc Biol 1996, 16:1399-1405.
53. Poliakova L, Kovesdi I, Wang X, et al.: Vascular permeability effect of adenovirus-mediated vascular endothelial growth factor gene transfer to the rabbit and rat skeletal muscle. J Thorac Cardiovasc Surg 1999, 118:339-347.
54. Lazarous DF, Shou M, Scheinowitz M, et al.: Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 1996, 94:1074-1082.
55. Horowitz JR, Rivard A, van der Zee R, et al.: Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997, 17:2793-2800.
56. Lehrman S: Virus treatment questioned after gene therapy death. Nature 1999, 401:517-518.